SCHEMBL1670775

SCHEMBL1670775

O=C1CC(=O)c2ccccc2C1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 3/20 0.62
BCHE P06276 2/20 0.62
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
CDC25B P30305 3/20 0.55
MAOA P21397 4/20 0.52
KDM4E B2RXH2 4/20 0.52
MAPT P10636 4/20 0.52
S100A4 P26447 3/20 0.52
APAF1 O14727 3/20 0.52
POLB P06746 3/20 0.52
RAB9A P51151 3/20 0.52
TDP2 O95551 2/20 0.52
LMNA P02545 2/20 0.52
BLM P54132 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
PTPRC P08575 2/20 0.52
CES2 O00748 1/20 0.52
TERT O14746 1/20 0.52
NPC1 O15118 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11290381 0.97 CES1 (0.60) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL11293121 0.97 CES1 (0.60) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL11287850 0.97 CES1 (0.60) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL29353628 0.89 CES1 (0.52) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL88188 0.89 CES1 (0.52) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL31741221 0.86 CES1 (0.50) CES1BCHEMEN1KMT2ACDC25B
Ammonia Solution, Strong SCHEMBL28310427 0.86 CES1 (0.50) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL28195032 0.86 CES1 (0.50) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL10556518 0.86 MAOA (0.53) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL3275841 0.80 CES1 (0.52) CES1BCHEMEN1KMT2ACDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021042001-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES Natural Extraction Systems, LLC (US) 2021-03-04 WO claimed
US-9717699-B2 Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides ADHEZION BIOMEDICAL, LLC (US) 2017-08-01 US claimed
US-20160331700-A1 Sterilized Compositions of Cyanoacrylate Monomers and Naphthoquinone 2,3-Oxides H.B. FULLER MEDICAL ADHESIVE TECHNOLOGIES, LLC. 2016-11-17 US claimed
US-20150283290-A1 STERILIZED COMPOSITIONS OF CYANOACRYLATE MONOMERS AND NAPHTHOQUINONE 2,3-OXIDES ADHEZION BIOMEDICAL, LLC (US) 2015-10-08 US claimed
EP-1300428-B1 (Meth) acrylic crosslinked fine particles and method of manufacturing the same NIPPON CATALYTIC CHEM IND (JP) 2009-01-14 EP claimed
EP-1300428-A2 (Meth) acrylic crosslinked fine particles and method of manufacturing the same Nippon Shokubai Co., Ltd. (JP) 2003-04-09 EP claimed
US-20030064237-A1 (Meth)acrylic crosslinked fine particles and method of manufacturing the same NIPPON SHOKUBAI CO., LTD. (JP) 2003-04-03 US claimed
EP-0502964-B1 USE OF COMPLEX LIGANDS FOR IONS IN FERROELECTRIC LIQUID CRYSTAL MIXTURES HOECHST AG (DE) 1995-02-22 EP claimed
CN-117062636-A Catheter securement compositions and methods 艾德合森生物医药有限责任公司 2023-11-14 CN disclosed
US-20220218951-A1 CATHETER SECUREMENT COMPOSITIONS AND METHODS PROVIDING SIGNIFICANTLY STRONG SECUREMENT, WATER RESISTANT SEAL, EFFECTIVE HEMOSTATIS, AND ANTIBACTERIAL PROPERTIES AT AND AROUND VASCULAR ACCESS SITES H.B. FULLER MEDICAL ADHESIVE TECHNOLOGIES, LLC. 2022-07-14 US disclosed
US-11083717-B2 Compositions and methods for drug sensitization of parasites THE TEXAS A&M UNIVERSITY SYSTEM (US) 2021-08-10 US disclosed
WO-2021042001-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES Natural Extraction Systems, LLC (US) 2021-03-04 WO disclosed
CN-109791222-B Transparent substrate having anti-glare and anti-reflection properties and method for manufacturing same 福美化学工业株式会社 2020-12-29 CN disclosed
WO-2020251015-A1 2-ALKYLCARBONYL[2,3-b]FURAN-4,9-DIONE PRODUCTION METHOD AND PRODUCTION INTERMEDIATE THEREFOR 大日本住友製薬株式会社 2020-12-17 WO disclosed
EP-0575143-A2 Resinous particles, method for production thereof, and uses therefor NIPPON SHOKUBAI CO., LTD. (JP) 1993-12-22 EP disclosed
EP-0385688-A2 Ferroelectric liquid crystal composition and ferroelectric liquid crystal display device MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1990-09-05 EP disclosed
EP-0172427-B1 PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER Shin-Etsu Chemical Co., Ltd. (JP) 1989-07-05 EP disclosed
US-4758639-A Process for production of vinyl polymer SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-19 US disclosed
US-4757124-A Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-12 US disclosed
EP-0172427-A2 Process for production of vinyl chloride polymer Shin-Etsu Chemical Co., Ltd. (JP) 1986-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11083717-B2 Compositions and methods for drug sensitization of parasites ABCC1, SLC11A2, ABCG2 CES1 483/4885BCHE 924/4885MEN1 3828/4885
US-20160331700-A1 Sterilized Compositions of Cyanoacrylate Monomers and Naphthoquinone 2,3-Oxides PROC, CCNK, MMS19 CES1 3295/4885BCHE 4324/4885MEN1 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.